Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Motor Activity 1Lymphoma, Follicular 1Colitis, Ulcerative 1

Interventions

Rituximab 377Cyclophosphamide 180Bendamustine Hydrochloride 110obinutuzumab 100Vincristine 95fludarabine 92Prednisone 90Doxorubicin 90ibrutinib 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24Prednisolone 23tositumomab I-131 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × peficitinib × Lymphoid × Clear all
NCT01959282 2019-01-04

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development, LLC

Phase 2 Completed
219 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular, Motor Activity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡